Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients
Immunotherapy in the form of ICIs has revolutionized advanced NSCLC treatment algorithms, with ICI-containing combination treatments being the latest addition to approved regimens. However, PD-L1 still represents the only routinely assessed and validated biomarker apart from genetic drivers testing,...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI AG
2021-06-01
|
| Schriftenreihe: | Journal of Molecular Pathology |
| Schlagworte: | |
| Online-Zugang: | https://www.mdpi.com/2673-5261/2/2/17 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|